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Abstract
Xenotransplantation is a breakthrough medicinal technology that is an attempt to change the lives of millions of people.  The 
problems in the current organ transplant system risk the lives of patients each and every day.  Intense waiting periods and 
extremely costly procedures exemplify the stress and pressure that these patients face as an attempt to save their own lives. 
Xenotransplantation is the idea of growing human organs in a different species, using incredible stem-cell and CRISPR technology. 
This can introduce an answer to some of the issues in the current transplant system.  Many technical and ethical issues are 
becoming relevant with the introduction of this new medical phenomenon.  If these barriers can be overcome, xenotransplantation 
can offer a quicker, cheaper, and more effective option for patients in need of an organ transplant. 
Xenotransplantation:The Science, the Advantages, 
the Ethics
Chana Erlbaum
Chana Erlbaum graduated June 2018 with a B.S. degree in Biology and will be attending the Physical Therapy 
program at Touro College
Introduction
Thousands of sick patients are in desperate need of an organ 
transplant, often having their entire lives depending on this one 
vital procedure. Before they can undergo treatment, a proper 
organ donor must be found, and the process is harder than 
ever imagined. Numerous factors affect the long waiting time, a 
period that can frequently become over a year. The main slow-
down is the simple shortage of organs ready for transplant. In 
response to the overwhelming need for organ donations, new 
medical research is being explored as an attempt to alleviate the 
high demand. Xenotransplantation poses as a possible solution 
to this problem and has the capabilities to be very helpful in the 
medical world; releasing the great amount of stress and anxiety 
involved in the classic organ transplant system that is now in 
place. However, this new medical process introduces new bio-
medical and ethical issues. Scientists and doctors are currently 
exploring the possibilities of this new technology, weighing the 
costs against the benefits; an important attempt to improve the 
medical world of organ transplantation.
History of Organ Transplants
The concept of organ transfer in a procedural sense has been 
around for centuries, in-fact cases of organ transplantation dates 
back to ancient times. There is even written proof and docu-
mentation from archeological records that suggest that organ 
and tissue transplantation is thousands of years old. However, 
modern-day organ transplantation is a relatively new medical 
phenomenon that has saved the lives of millions of people from 
end-stage organ failure. 
In the early 1900’s, Dr. Alexis Carrel experimented with kid-
ney transplantations in cats, becoming the first surgeon to ex-
plore vascular surgery (Howard et.al., 2012).  Carrel’journey to 
organ transplantations started with success in vascular surgery 
and suturing of vessels. These experiments also advanced the 
knowledge of organ preservation, showing that human tissue 
could be stored in either saline solution, the patient’s serum, 
or defibrinated blood, until it is needed. Carrel then went on 
to organ transplantations, experimenting with kidney transplan-
tations between dogs, and from dogs to cats. He realized that 
the animals only lived with the transplant for a short period 
of time and he knew that there was some sort of rejection 
going on in the host’s body. Alexis Carrel made extraordinary 
advancements in the medical exploration of organ transplants 
and created the possibility for more research in this area 
(Rothwell, 2011). In 1923, Dr. Harold Neuhof wrote a book 
called The Transplantation of Tissues, which revealed the work 
of many different tissue transplants including skin, cornea, mus-
cle, pancreas and nerve tissue (Howard et.al., 2012).
Soon after, the first human kidney transplant was recorded 
using a kidney from a donor that had died six hours prior. The 
blood type of the donor was type B and the recipient was type 
O, which prevented the kidney from functioning, leading to the 
patient’s death. However, this may not have been the only cause 
for the disfunction of the kidney as other trials have also been 
proven unsuccessful. In 1953, a kidney transplant was done from 
mother to son which only lasted three weeks before the re-
cipient rejected the donor organ. In the beginning years of the 
1950’s, Dr. David Hume performed almost ten kidney transplan-
tations which are now considered the first of their kind in the 
modern era of transplantation. However, none of the recipients 
had a long-term survival after their kidney transplant. 
These and other trials revealed that such organ transplants 
would not be possible without immunosuppressant drugs. With 
this development, organ transplant became a real option for 
patients with organ failure. Dr. Joseph Murray performed the 
first successful kidney transplant in 1962, leading into many 
other victorious cases around the world. The ‘60’s were very 
progressive years for this specific research and medication, as 
the first lung and heart transplants were also done during this 
time (Howard et. al., 2012). 
Problems With the Current Organ Transplant 
System
As immunosuppressant drugs allowed organ transplantation to 
start becoming a viable option for victims of organ failure, the 
need for transplantable organs became overwhelming. In the past, 
kidneys from living donors were being used, but this supply is lim-
ited and not nearly enough to provide for all in need. Even with 
deceased donors for transplants, the available donor organs, un-
fortunately, do not cover the demand (United Network for Organ 
Sharing, Data, 2018). 
Although most technical problems involved in the process have 
been solved, organ transplantation is not seen as a long-term cure 
for patients as there are still biological issues and financial problems. 
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The biggest and most complicated problem is the patient’s 
rejection of the new organ. When a patient undergoes an organ 
transplant surgery, the body’s immune system becomes stim-
ulated against the “foreign” organ and tries to kill it. Patients 
are usually given strong medication to suppress their entire 
immune system, but that can become counterproductive as the 
patient is now vulnerable to other diseases. Different drugs, 
such as Cyclosporin, have been approved to control much of 
the rejection, but transplantations can still have those dangerous 
effects (MTF Biologics, 2017). Although they have been shown 
to improve symptoms, these drugs can have many negative side 
effects including tremors and seizures. 
Another problem is the long waiting period that patients wait 
in order to receive a proper match for donation. There are sim-
ply not enough donors to fill the demands, causing many victims 
to die in the ‘waiting room’. Although the shortage of organs is 
the main cause for the waiting time, the length that the patient 
waits can vary, depending on a number of factors. The blood or 
tissue type, the size of the organ, and the medical urgency of the 
situation are some factors that will fluctuate the waiting time. In 
any case, the patient almost always needs to wait for a proper 
donor before proceeding with the transplant. This is not practical 
in many cases when the organ transplant is extremely urgent. On 
average, twenty people die every day while waiting for an organ 
donor (United Network for Organ Sharing, Data, 2018). 
Also, organ transplants are extremely costly and many people 
simply cannot afford such medical procedures. Kidney trans-
plants cost over four hundred thousand dollars, and a heart 
transplant goes up to over one million (Rapp & Vandermey, 
2017). This cost does not even include the health maintenance 
of such a procedure, nor the cost of immunosuppressant drugs 
that cost as much as ten thousand dollars per year, for life 
(Gordon, et. al. 2008). 
Methodology of Xenotransplantation
Looking for a solution to this unmet medical need, re-
searchers have come up with a new method known as 
Xenotransplantation, which is the process of “grafting or trans-
planting organs or tissues between members of different spe-
cies.”  Xenotransplantation is using stem-cell and CRISPR tech-
nology to grow human organs in a host of a different species. 
This idea comes from chimerism, the ability to create a “living 
thing that is composed of cells from two or more organisms” 
(Dunlap, 2017). The basic procedure is to use the pig as a host 
by cutting out the HOX genes that code for growing certain 
organs and the genes that code for porcine microorganisms 
from their genome. HOX genes are the sequence of genes in 
the genome that directs the body organization in an embryo 
(KhanAcademy, Khanacademy.org, 2018).  Using CRISPR-Cas9 
technology, described below, genetic engineers can knock out 
the genes in the pig that code for the development of specific 
organs, and replace them with specialized human stem cells that 
will grow human organs instead. The hypothesis is that infusing 
differentiated human stem-cells into this embryo will result in 
the pig growing a human organ instead of its own.
CRISPR-Cas9 Technology
CRISPR-Cas9 stands for Clustered Regularly Interspaced Short 
Palindromic Repeats, and is breakthrough technology in genome 
editing. CRISPR is a special region in DNA that is characterized 
by having repeated nucleotides and spacers. This unique DNA 
region was first recognized in bacterial genomes and has since 
been adapted in the laboratory as the CRISPR Cas9 complex 
(Vidyasagar, 2018). Cas9 is a protein that acts as the molec-
ular scissors that can cut the DNA in a double-strand break. 
When combined with a guide RNA (sgRNA), it forms the Cas9 
Complex. The Cas9 first binds to a sequence in the genome 
and the guide RNA unwinds the double helix. The guide RNA 
is precisely designed to match up with the specific strand of 
DNA that needs to be edited. Then, the Cas9, with the help of 
its nuclease domains, cuts the DNA, creating a double-strand 
break in the double-helix. The DNA tries to repair itself but the 
reparations are usually flawed which inevitably shuts off that 
particular gene.  This is why CRISPR is “a great tool for knocking 
out specific genes” (NatureVideoChannel, 2017). 
Stem-Cell Research
Another biomedical technique is somatic cell nuclear transfer, 
known as SCNT, or cloning. Conceptually, the nucleus from a 
somatic (body) cell replaces the nucleus in a fertilized oocyte of 
another individual. This hybrid blastocyst is capable of generating 
a stem cell line” (Columbia.edu, 2018). The created stem cells 
will be identical to the donor and have many uses in the medical 
field. One such example would be to use these cloned cells to 
create human organs in pigs a step in the xenotransplantation 
process. The idea is to fuse the stem cells from the patient into 
a porcine embryo, hoping that the pig will grow human organs 
that can then be used as the transplant for the intended patient. 
In a few short months, the patient could potentially be on his/
her way to a complete recovery. This will only be a possibility, 
however, if the barriers of Xenotransplantation are overcome. 
Brief History of Xenotransplantation
Aside from cross-species blood transfusions, which were 
around since the 17th century, skin grafts are considered the 
first attempted trial in xenotransplantation. Skin grafts from an-
imals to human patients were performed as early as the 19th 
century. Frog skin was the most popular species to was the 
most frequent source of the donor material to the skin grafts. 
Different attempts at xenotransplantation were tested, mostly 
using primates as the donor animal. Out of thirteen trials, only 
one kidney transplant from a chimpanzee to a human patient 
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was successful with the patient living for an entire nine months 
before dying as a result of rejection of the kidney.  In 1964, 
the first heart xenograft from a chimpanzee to a human was 
performed. The patient died within two hours of the operation. 
Later, in 1992, a doctor named Starzl performed a baboon to 
human liver transplant, with the patient surviving for seventy 
days. Along with the numerous failures, some of the early xeno-
transplants resulted in temporary patient survival. But, in gener-
al, the organs were rejected in an even more serious case than 
with a same-species transplant. The rejections of this kind are 
so severe that immunosuppressive drugs are not strong enough 
to stop the rejective response to the xenografts (Cooper, 2015)
The Advantages of Porcine Xenotransplantation
Recently, the focus has been on the use of organs from the pig 
and hog family, porcine, as they are comparable to human or-
gans in size, anatomy and physiology, compared to other species 
(Niu, Wei, & Lin, 2017). Pigs, compared to other species such as 
baboons, would be a valuable candidate for organ xenotrans-
plantation. Pigs can be bred in large herds and with a relatively 
short maternity period, making them a more available option. In 
addition, they are not a costly animal to breed (Cooper, 2015). 
The advantages of xenotransplantation from pigs would be 
enormous, starting with the obvious increase in availability of 
organs for transplantation. Right now, there is a shortage of 
human organs for transplants, but using organs from another 
species will solve this problem, it will also make immediate 
transplant surgery possible for patients with an urgent situation. 
In addition, organs that are retrieved from human cadavers have 
already experienced the trauma of brain death which may lead 
to other issues later on. With animal donor organs, the organs 
will be removed from a healthy pig that is under anesthesia, 
avoiding the problem altogether. Another important solution 
that xenotransplantation brings is the decrease of the risk of 
a pathogen being transferred from the donor to the patient. 
Diseases such as the West Nile Virus and rabies have been 
passed through organ transplant surgery resulting in a number 
of deaths. The pigs intended to be used for xenotransplantation 
are being raised in the best conditions and are being supervised 
closely which reduces the likelihood of any illness to be trans-
ferred from donor to patient (Cooper, 2015).
Zoonoses and Porcine Endogenous Retrovirus 
(PERV)
CRISPR-Cas9 can be used in xenotransplantation research by 
knocking out specific genes in the pig that cause rejection when 
transplanted into human patients. Zoonoses are diseases that 
are transferred between humans and animals, caused by bac-
teria, parasites, and viruses. These diseases pose the major bar-
rier preventing xenotransplantation from becoming proto-call 
in the medical world. The potential transfer of porcine related 
infections into the human genome is a major risk of xeno-
transplantation. The pig herds intended to be used for medical 
reasons have been raised under the most sanitary conditions 
and have been screened for most pathogens and viruses that 
can possibly harm the recipient. However, porcine endogenous 
retroviruses that lie in the porcine genome have the capability 
to hurt human health. PERV are viral elements in the porcine 
genome, and being that they are innately a part of the DNA, the 
retroviruses cannot be eliminated by means of selective breed-
ing or drugs. PERVs have the ability to recombine with other 
genetic elements of the recipient’s genome. Similar to pigs, hu-
mans have their own set of endogenous retroviruses, known as 
human endogenous retroviruses, or HERVs. If the PERV were to 
come in contact with the human endogenous retroviruses, the 
former genes can recombine and disturb the human genome. 
Naturally, the HERVs are attempted to be halted by some sort 
of stop codons or deletions, but some bypass the stop codons 
and actually “play an important role in human physiology as well 
as in pathogenesis” (Machnik, et al., 2014).
Studies of HERVs have concluded that class I of HERVS group 
together with γ- and ε-retroviruses, and during a xenotrans-
plantation it is these genes that can recombine with PERVs that 
also belong to the γ-retroviral group (Machnik, et al., 2014). 
Studies have recently confirmed that two out of three PERV 
types, namely PERV-A and B, have been seen to replicate in 
human cells during in-vitro research, meaning in a clinical setting. 
To date, no PERV infection of human cells have been document-
ed in-vivo, but the possibility of this occurring needs to be taken 
into real account as new pathogens can be created at the point 
of interaction, and these new pathogens can cause unpredict-
able damage (Prabha & Verghese, 2012).
Recent discoveries, however, have shown major advancements 
in this area. Scientists have used CRISPR technology to success-
fully cut out sixty-two PERV sequences from a porcine genome. 
The nuclei of these cells were then transferred into enucleated 
pig oocytes by somatic cell nuclear transfer, and then implanted 
into surrogate female pigs. The results were astonishing with 
thirty-seven piglets being born, all with inactivated PERVs in the 
genome. This research greatly expands the possibilities in the 
realm of xenotransplantation, although other issues are yet to 
be resolved (Denner, 2017).
The Issue of Rejection
With all the prementioned advantages, there are still barriers 
preventing pig organ xenotransplantation from becoming the 
standard medical procedure. Scientifically speaking, the biggest 
barrier to overcome is the problem of rejection; the patient’s 
natural response to an alien in the body. Firstly, within seconds 
or minutes of the transplant, the possibility of hyperacute 
rejection can happen. This type of rejection occurred when 
pig organs were transplanted into nonhuman primates. The 
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preformed antibodies of the receiver attached themselves to 
the pig’s vascular endothelium and as protocol reaction to a 
pathogen, the cascade system was initiated. This caused the en-
dothelial cells to convert into procoagulant phenotypical cells, 
resulting in hyperacute rejection. Attempts have been made to 
prevent this by depleting the antipig antigens, or the comple-
ment system from the recipient’s serum, however, there are 
still other forms of rejection that may occur.  Acute humoral 
xenograft rejection may occur during the first few days after the 
transplant, and cellular rejection can become a problem even 
weeks after the operation. This rejection is acute-cell mediat-
ed, meaning that different cells in the patient’s body recognize 
the foreign organ as unfamiliar and begins to attack it. The cells 
involved are usually the natural killer cells, macrophages, and 
cytotoxic T cells. It is believed that even immunosuppressant 
drugs cannot prevent this rejection from being triggered. If the 
recipient is able to survive with the graft for a longer period of 
time, chronic rejection may occur. The exact cause of this type 
of rejection is not completely understood. However, the main 
point regarding all types of rejections is that the antibodies or 
killer-cells in the recipient attack the donated graft, resulting in 
a slow, but ultimately fatal destruction of that organ (Esker & 
Cooper, 2010). The information regarding the rejection or ac-
ceptance of a pig organ in a human patient is extremely limited, 
as only a few procedures have been tested so far. The scientists 
and doctors cannot study this further until a patient survives 
the procedure for a longer time (McLean & Williamson, 2004). 
Rejection of the organ can occur in any transplant, regardless 
of whether the graft is from the same species or not. The differ-
ence is that in a xenotransplant rejection, the immunosuppres-
sant drugs are not strong enough nor sophisticated enough to 
significantly extend the patients survival time. 
Potential Solution for Xenograft Reject
Genetic Engineering of the pigs is the newest and most success-
ful method to date to prevent or mitigate the rejection of the 
organ graft. One major advancement is the creation of a genet-
ically engineered pig that expresses a human complement-reg-
ulatory protein. This protein is found in the pig’s vascular endo-
thelial cells and protects the tissue of this donated organ from 
being attacked by the pre-formed antibodies during hyperacute 
rejection (Bloom, Moulton, McCoy, Chapman, & Patterson, 
1999). Genetic engineers have also produced pigs which have 
had the gene for α1,3-galactosyltransferase removed. The gene 
for α1,3-galactosyltransferase codes for the production of the 
enzyme that adds Galα1,3Gal oligosaccharides to different basic 
glycoproteins and glycolipids in pigs. In general, Gal is a major 
target for the human antibodies, as it is seen as a major invader. 
The removal of this gene, and therefore the halt of the Gal pro-
duction in the pigs, has significantly reduced the hyperacute re-
jections that usually occur during the pig to nonhuman primate 
xenograft trials (Esker & Cooper, 2010). 
The results of this research have been positive; the length of 
survival time increasing by the use of the genetically engineered 
pig organs. A pig heart of this type lasted for 3-6 months, kidneys 
for close to three months, and livers for days. The extension 
of the survival period is proof of the success of the genetic 
research (Esker & Cooper, 2010).
There are also genetic solutions being studied that will disable 
the natural killer cells and the macrophages from attacking the 
xenograft, although they have yet to be tested in pig to non-
human-primate transplant. Genetic engineers are working on 
producing pigs that are HLA-E or HLA-G transgenic as these 
immunoregulatory molecules are expected to stop natural kill-
er cell cytotoxicity (Esker & Cooper, 2010). 
The Issue of Coagulation Dysregulation
Another barrier that has arisen during the xenotransplanta-
tion trials is the development of thrombotic coagulopathy and 
consumptive coagulopathy, different types of coagulation dys-
regulation. Coagulation dysregulation is irregular blood clotting 
in areas of the circulatory system. The xenograft recipient will 
usually develop one of these, or possibly both, which poses a big 
limitation to the survival time of the graft. In heart transplants 
from genetically modified pigs to baboons, thrombotic coagu-
lopathy is the predominant symptom, while in the kidney graft, 
the baboon developed consumptive coagulopathy. It is thought 
that physiological differences between pigs and primates are the 
causes for these problems, although the exact reason for the 
coagulation dysregulation development remains unclear. It is 
known, however, that activated endothelial cells of the donated 
organ are the cause for inflammation and coagulation in the 
recipient. Ischemia, or inflammation, is inevitable in most types 
of organ transplants, but various types of intertwined factors 
can be the cause of graft endothelial cell activation (Cowan, 
Robson, & d’Apice, 2011). One proposition suggests that the 
endothelial cells activated by either the antibodies or the start 
of the complement, increase the activity of TF, tissue factor. 
The introduction of the TF into the portal vein activates the 
instant blood-mediated inflammatory reaction, known as IBMIR. 
Characteristics of IBMIR are platelet binding, complement acti-
vation, and thrombosis (Esker & Cooper, 2010). 
Ethical Problems With Xenotransplantation
In addition to the biological barriers of Xenotransplantation, 
problems regarding ethical and moral topics come into question 
when researching the possibilities for the future. Transplantation 
in general has a public risk associated with the administration of 
immunosuppressant drugs. These drugs are known to lower the 
patient’s ability to fight off infections, and therefore increase the 
risk of contamination. For the patient, the risks involved need 
to be weighed by their own physician; however there are public 
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concerns involved as well. The new genetic engineering, plus the 
previously used immunosuppressant drugs, have the potential to 
“open the way for the emergence of new viral mosaics into the 
general population” (Anderson, 2006). 
The opposing side of the ethical debate brings up valid points 
as well. With thousands of people in desperate need of organ 
donations, is it ethically fair to deprive them of the possible solu-
tion that can potentially save so many lives? The introduction of 
xenotransplantation can greatly reduce the waiting period for an 
organ donation, and additionally provide the patient with a long-
term graft. The immunosuppressant drugs have saved so many 
people from death; is it morally okay to ban them on the slight 
chance that they can cause an infection outbreak? These ques-
tions are some of the many that have come up in discussion over 
the last couple of years, as the medical world is coming closer to 
introducing this new phenomenon to regular medical protocol.  
Another ethical problem involved in xenotransplantation is 
the issue of personal privacy and confidentiality. This question 
arises due to the necessity of monitoring of the patient after 
an organ transplant, going as far as to institute a lifetime sur-
veillance of the patient. This surveillance has become a part of 
the system as an attempt to prevent pathogenic diseases from 
spreading through organ transplant surgery. As previously dis-
cussed, the pathogenic risks involved in xenotransplantation are 
very great and have caused medical outbreaks in the past. In 
fact, in the year 2000, a hepatitis C breakout was reported due 
to an infected donor that was mistaken to be healthy. Since 
then, tremendous precautions have been taken while looking 
for organ donors, as the transfer of pathogens through trans-
plants can lead to numerous fatalities. Opponents of the mon-
itoring system believe that this provision is an invasion of the 
patients’ privacy, as well as the privacy of their family and friends. 
Here lies the question whether or not the invasion of privacy 
is considered to be ethical for the safety of the patien and the 
“problem of maintaining ethical standards in situations such as 
this is vexing” (Anderson, 2006). 
The only possible way to effectively protect society from infec-
tious diseases via xenotransplantation is if the national and inter-
national powers decide on a logical system, keeping the ethical 
debates in mind. The World Health Organization has previously 
come together to discuss this exact topic, although no agreement 
was yet to be decided.  To date, the only guidelines put in place 
are those of the Food and Drug Administration’s Recombinant 
DNA Advisory Council. The RAC approved gene recombination 
studies to be done at Harvard and MIT, advancing the medical 
research of this field. The RAC’s permission was granted with 
the consent of the citizens of Massachusetts, justifying the ethical 
questions involved in such research (Anderson, 2006). 
The American Society of Transplant Physicians voice their 
concern of infectious diseases being spread internationally. They 
feel that United States regulations are not strong enough in 
comparison to the severity of the risk involved. It is presently 
legal for patients in need of an organ donation to receive or-
gans from live donors living in impoverished countries, where 
infections are known to be rampant. For example, there is a 
website named Liver4you.org which arranges liver donations 
from people in the Philippine Islands. Bringing these diseases 
across to the United States through the organ transplant poses 
as a major threat to the wellbeing of society (Anderson, 2006). 
Often, doctors and surgeons are also researchers of new 
xenotransplantation medication, which poses additional ethical 
questions regarding the split between their medical responsi-
bilities and their personal studies. The physicians can frequently 
be confronted with “the well-being of the patient in direct op-
position to the advancement of academic medicine” (Anderson, 
2006). An example of what might result from such a situation 
is a doctor convincing a patient to participate in a clinical trial 
that he/she would otherwise not join. An infamous case of this 
sort, known as the Baby Fae case, took place in 1984 when a 
young child was used in a medical trial of a xenotransplantation 
using a baboon heart. The parents were encouraged by optimis-
tic doctors who hoped to provide the baby with “immediate 
and long-term survival” but she only survived for four weeks 
following the graft. Medical researchers have become cautious 
getting involved in xenotransplantation studies in fear of this 
sort of issue cropping up, in addition to the history of medical 
science misconduct (Anderson, 2006). 
Additionally, with the introduction of stem cells into the pig 
embryo, the possibility of creating a pig with human elements 
presents an ethical issue. The ethical debate discusses the pos-
sibility of human gametes to be created and an embryo to be 
formed as an interspecies chimera. Although it is agreed upon 
that the embryo would not be able to develop, the mere cre-
ation of it poses as an ethical question. Also, the differentiation 
of human stem cells needs to be studied in depth as the ques-
tion arises of what is stopping the stem cells from entering the 
pig’s brain, or other areas, which will blur the margin of what is 
considered human and what is considered animal? Is it morally 
permissible to perform a procedure that can potentially give a 
pig, human, high-level brain functions? These ideas are unlikely 
in the scheme of things, but pose concerns in the biomedical 
world nonetheless (Masaski & Nakauchi, 2017). 
Conclusion
Scientific researchers are constantly trying to better the med-
ical world; looking for solutions and applying their incredible 
knowledge to helping humanity.  The biomedical field is ex-
ploring the possibilities of genetic engineering combined with 
stem-cell research, hoping for xenotransplantation to one day 
become a standard medical procedure for patients with organ 
failure. When it comes to genetic engineering, the possibilities 
are endless; however, xenotransplantation has many barriers to 
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overcome before it can become the standard medical proce-
dure. However, the latest research may explore the best course 
of action regarding this dynamic research. Researchers have 
proposed for xenografts to be used for patients in the waiting 
period that are waiting for an organ donor. This way, although 
xenotransplantation is not yet a final solution, it will at least 
minimize the number of deaths of patients, and the health risks 
for waiting for a proper transplant.  This change in proto-call 
has the tremendous potential to save millions of lives, giving the 
patient the ability to live the few months until they can receive 
a proper transplant. Researchers are only beginning to uncover 
the technology’s tremendous potential and long-term survival 
of xenografts may be a few years away. Even so, it is possible that 
for now, temporary xenotransplantation can be the life-saving 
procedure that patients are hoping for (Servick, 2017). 
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